For the First Time, the FDA Takes Back a Breakthrough Therapy Designation
Insights - Merck (MRK) revealed on Wednesday that the U.S. FDA has rescinded a Breakthrough Therapy Designation for its investigational Hepatitis C treatment.
Read nowMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
Biotech Stocks Will Rip Higher in 2015 Because the Patriots Took Super Bowl XLIX
UniQure: A Dark Horse in the Gene Therapy Field
Research - We see uniQure (QURE) as a dark horse in gene therapy, in-part because of numerous catalysts in 2015 that will put fresh eyes on this European company.
Read now
These Biotech IPO’s Just. Don’t. Stop.
Your 30-Second Primer on this Week’s Hottest IPO, Spark Therapeutics
Insights - Spark Therapeutics (ONCE) lists publicly today, joining companies like bluebird bio (BLUE) and Avalanche (AAVL) as yet another emerging gene therapy player.
Read now
Intercept Gains a Cool Billion in After Hours Trading
Insights - Intercept Pharmaceuticals (ICPT) added over $1 billion to its value in late trading when its lead drug received a Breakthrough Therapy Designation
Read now
Conatus’ Recent Data were so Damn Confusing; Sometimes That’s the Best Thing for Investors
Research - Conatus (CNAT) was punished 2 weeks ago with the release of results from 3 phase I/II studies. Thankfully, we suggested taking profit beforehand at +60%.
Premium